Articles tagged with Pharmaceutical Industry
A new pesticide development with integrated sunscreen shields chemicals from UV light, increasing their effectiveness and reducing degradation. The technology has the potential to lower costs for farmers and minimize environmental impact.
Researchers apply slag to wheat growing in greenhouses, causing plants to grow spiky structures that repel rabbits, reducing grazing damage. The environmentally friendly method uses a plentiful byproduct of blast furnaces and could circumvent pesticide regulatory approval.
Researchers identify barriers and opportunities in treating mental illness, proposing a new paradigm for CNS drug development. The study highlights the need for more effective treatments with fewer side effects, focusing on treatments that act on multiple molecular targets.
Researchers develop an alternative to animal testing by tricking ticks into setting up home on faux-cow hides. This method measures leg tremblings of ticks to observe early signs of pesticide toxicity.
A study found that feeding babies alcoholic milk may protect against some food allergies. Kefir's friendly bacteria block the pathway involved in allergic responses, reducing IgE levels and activating cells responsible for histamine release. The research suggests kefir could be a promising tool in preventing allergies.
Five experts recommend Congressional action to address eight major problems, including inadequate funding and expertise. They propose five key changes to strengthen FDA's ability to assure public safety.
Researchers at Northwestern University have developed a new method to sort single-walled carbon nanotubes by their diameter and electronic structure, overcoming the problem of structural heterogeneity that has limited their widespread use. This method, which exploits subtle differences in buoyant densities, promises to enable the produ...
A US survey of obstetricians and gynecologists found that one in three doctors believe free drug samples impact their prescribing choices. More than half of respondents felt it was ethical to accept free samples or lucrative consultancy offers from pharmaceutical companies.
UCR researchers develop more stable carbene, a family of compounds used in pharmaceuticals and petrochemicals. The new molecule has a unique shape and size, potentially leading to even more powerful catalysts.
The UQ Centre for Integrated Preclinical Drug Development is developing new tools to streamline the preclinical trials process. This will improve productivity across the pharmaceuticals industry and address a blockage in the drug production pipeline.
Renowned clinicians call for collaborative effort to revive clinical pharmacology in the UK. The Lancet experts advocate for joint action by medical schools, government bodies, and industry partners to bolster this crucial field.
The Yale guidelines ban faculty from receiving gifts, meals, and free drug samples from industry, setting standards for financial conflict of interest disclosure in educational programs. The guidelines aim to promote an effective and ethical partnership between medical schools and pharmaceutical companies.
The University of Queensland is leading a world-first consortium to create an Australian Minerals Science Research Institute, funded by a $8.6 million ARC grant. The five-year research program will focus on sustainable mining and mineral processing, with potential applications in industries such as pharmaceuticals and food production.
Agnès Vignery, an expert in bone development, will conduct collaborative research at Pfizer's Global Research and Development. Her lab has developed a new technology to induce bone formation for fracture prevention, which is being refined in rodents for human translation.
University of Oregon chemist Jim Hutchison has developed a method to rapidly generate diverse libraries of functionalized gold particles with cores of 11 gold atoms. The new synthesis technique offers great promise for research and development at the nanoscale.
Researchers at Queen's University have developed switchable solvents that enhance chemical manufacturing processes while minimizing waste and emissions. This breakthrough enables more environmentally-friendly chemical production methods.
ERDITI, a collaboration between pharmaceutical companies and academic researchers, aims to repurpose 'abandoned' compounds for rare diseases. The initiative, launched by Alain Fischer, could lead to discoveries of effective treatments and profitable new drugs.
Research by industry faces no high standard, enabling pharmaceuticals, tobacco, and other industries to make claims harder to challenge than government-funded research. The current imbalance can be seen in the FDA's increasing scrutiny, with a focus on
Bioethicists who accept funding from pharmaceutical and biotechnology industries may be more likely to prescribe industry drugs, even if they believe it has no influence. Researchers argue that stronger measures are needed to ensure independence and credibility in bioethics scholarship.
Five high-profile medical whistleblowers share their accounts of practices in medicine and research that risk public health and safety. They reveal the 'pharma-FDA complex' may compromise drug development, prescribing, and safety monitoring, leading to potential disasters like Vioxx.
Medical schools have inconsistent standards for allowing industry sponsors to control research, including revising manuscripts, limiting investigator roles, and reviewing data. Some institutions prioritize public interest over sponsor interests, while others are more permissive, raising concerns about researchers' autonomy.
The Sapling Foundation grant will support OneWorld Health's efforts to develop new medicines for infectious diseases affecting the developing world. The Institute develops affordable treatments for diseases like visceral leishmaniasis, malaria, and diarrhea, with a focus on pre-clinical studies and clinical trials.
The production of sub-standard and fake drugs is a vast and under-reported problem that causes unnecessary deaths and illnesses. The authors argue that a multifaceted approach is needed to control the global epidemic of counterfeit and substandard drugs, including mandatory reporting by drug companies and governments.
The pharmaceutical industry is struggling with declining productivity and increasing R&D costs, prompting the need for innovative solutions. Personalized medicine offers a promising approach by targeting drugs to individuals likely to respond well, while regional development and cluster formation can foster collaboration and competitiv...
The conference will address patent regulations for genetically engineered organisms, regulatory challenges for new drugs developed through genetic investigations or stem-cell research, and public acceptance of these products. Experts with international reputations will discuss future pathways of innovation in the life sciences.
Pharmacogenomics has the potential to improve treatment successes and reduce adverse reactions by targeting specific drugs at specific patients. The industry is expected to bear a larger share of costs associated with drug-treatment failures as well-targeted therapies become more commonplace.
A Science magazine survey has identified top biopharma employers across two industries, with scientists in biotech and pharmaceuticals ranking highest for work-culture values alignment. The ranking takes into account 42 characteristics and attributes in seven categories, rating companies based on employee treatment, respect, and more.
The US postmarketing surveillance system requires major restructuring to effectively monitor drug safety. An independent agency would oversee the process, ensuring complete independence from pharmaceutical industry influence.
Clemson University receives a $600,000 NSF grant to support biomaterials research and the growth of an advanced materials industry cluster. The grant aims to facilitate technology transfer between academia and private industry, promoting economic development in South Carolina.
Norman, a morphine-free poppy variant, produces thebaine and oripavine compounds preferred by industry. CSIRO's Dr Phil Larkin and colleagues discovered genetic differences in Norman that facilitate its superior pain relief properties.
Researchers will develop tools for nano-scale manufacturing and apply them to biosensors for early disease detection and nanotube memory chips. The collaboration aims to create new products contributing 2 million jobs and $1 trillion in revenue by 2015.
The research highlights the importance of natural organohalogens, which are found in various organisms, including plants, animals, and insects. These compounds have medicinal properties, such as treating cancer, bacterial infection, and HIV, and serve vital purposes like hormones, pheromones, repellents, and natural pesticides.
The Presidential Green Chemistry Challenge Awards have honored scientists who develop innovative chemistry to lower pollution. Two winners in 2004 developed "tunable" benign solvents from water and CO2 that host chemical reactions more cleanly and efficiently.
The Canadian Medical Association recommends a national review of pharmacy prescription records confidentiality, calling for Health Canada to establish standards. The pharmaceutical industry should not be responsible for managing the issue.
A study of 332 randomized trials found industry-funded trials more likely to yield statistically significant pro-industry findings. Pharmaceutical companies prioritize trials with higher potential for positive results. This bias affects not only medical treatments but also new surgical interventions.
A Thai court case ruled in favor of patients with HIV-1, increasing access to essential antiretroviral drugs. Civil society groups played a crucial role in challenging multinational pharmaceutical industry practices, leading to improved treatment outcomes and increased self-image confidence among people living with HIV/AIDS.
A study by Michigan Medicine and Harvard University found that FDA review fees for drug companies haven't led to faster approvals. The researchers analyzed data from 843 new drugs submitted between 1977 and 2000 and found that staffing levels, not fee-based system, were responsible for the decline in approval times.
A researcher is developing photochemistry techniques that could help produce gasoline more efficiently and create new sensors for detecting pollutants. His work also has the potential to enhance the quality of microcircuitry and improve the aerospace and automobile industries.
The project aims to design microchannel reactors for on-site production of hydrogen peroxide, addressing transportation, storage, and dilution costs. The grant also supports the development of microchannel reactors for catalytic hydrogenation reactions in the pharmaceutical industry.
A new annotated compound library has been developed to speed up drug discovery, identifying 85 compounds that can inhibit tumor cell growth. The library's potential becomes clear as it can be expanded indefinitely and contains about 90% of all controlled substances and 50% of all drugs approved for use in the US.
A renowned chemist has won a prestigious award for his groundbreaking work on creating molecules found in nature, including lapidilectine B. He developed a new method to build nitrogen ring structures and successfully recreated the molecule step-by-step in the laboratory.
Researchers create experimental model of a non-equilibrium system to test the soundness of temperature in a continuously shaken container of tiny beads. They find that temperature follows the expected rules, suggesting that essential information can be extracted from disordered motion in dissipative systems.
Weizmann Institute scientists found that around 50 genes are optional, affecting a person's unique pattern of active olfactory receptors. This high level of genetic variation impacts how thousands of aromas and flavors are perceived. The study also shows varying levels of obliteration among different ethnic groups.
The Lancet appoints Dr. Tobias to a $15 billion programme tackling AIDS in African and Caribbean countries most devastated by the pandemic. Critics argue that his lack of knowledge about Africa and connections to the pharmaceutical industry may compromise his credibility.
A clinical trial found that early treatment with Atacand significantly reduced 12-month mortality and vascular events in patients with acute ischaemic stroke. The study also showed a comparable tolerability profile to placebo.
Researchers at UC Berkeley created a microbial factory that can produce artemisinin, an effective antimalarial drug, using yeast, wormwood, and bacterial genes. The process reduces the production of artemisinin to just a few chemical alterations, making it cost-effective for global use.
The University of Minnesota is leading a new initiative to create standardized safety protocols for genetically modified organisms (GMOs) in the agricultural biotechnology industry. This effort aims to address concerns about GMO safety and reduce regulatory stalemates.
Manzer has led the development of commercially viable replacements for CFCs, including HFC 134A in automobile air conditioners. He also designed catalysts that can make polycarbonate without generating another ozone-depleting compound as a byproduct.
Graham Dukes argues that the pharmaceutical industry prioritizes shareholder interests over global public health. He criticizes the industry's practices, including excessive pricing and promotional activities, which do not account for societal needs.
The pharmaceutical industry's focus on high-income markets is hindering access to essential drugs in less-developed countries, where millions lack access to life-saving medications. Voluntary licensing arrangements and freer trade could improve access to patented drugs, according to experts.
The pharmaceutical industry's political power can hinder effective drug regulation, leading to unsafe and ineffective drugs. A robust regulatory system is necessary to protect public health from the interests of the industry.
The pharmaceutical industry invests heavily in medical information, which can impact clinical practice and patient outcomes. However, this information is often kept secret, duplicated, and biased towards commercial interests, undermining public health needs.
According to Professor Rugman's research, only a handful of multinational companies, such as Nestlé and Unilever, can be considered 'global'. The majority focus on sales within their home region, with many struggling to maintain profitable foreign operations. This trend towards 'de-globalisation' is driven by persistently poor global p...
A study of internal tobacco industry documents reveals that companies profited from both tobacco and nicotine replacement therapies, undermining efforts to combat smoking addiction. Researchers argue that such financial conflicts of interest should be made public to ensure greater corporate responsibility.
A multidisciplinary team at Abbott Laboratories developed an innovative process to produce the protease inhibitor ritonavir, leading to the discovery of next-generation protease inhibitor lopinavir. This breakthrough has improved HIV/AIDS treatment outcomes and saved thousands of lives in the US.
A management science study finds public research has a significant impact on industrial R&D, with the pharmaceutical industry being a major beneficiary. The study reveals that public research contributes to both innovation and project completion, with materials science and computer science fields having the most widespread impact.
The American College of Physicians has updated its guidelines to ensure physicians maintain independence in patient care. The new advice urges individual physicians to avoid industry relationships that may compromise objectivity.
A study of 300 airline staff found that current smokers took almost three times as much sick leave as non-smokers, while ex-smokers had lower rates of absenteeism. Ex-smokers were also 5% more productive than current smokers, with productivity increasing over time.
Researchers at the University of Illinois Chicago have developed a fluorous chemistry-based method to convert alcohols into aldehydes and ketones, retaining the convenience of the Swern reaction. The new reagents eliminate the byproduct dimethyl sulfide, producing an odorless and easily recyclable alternative.
The book examines key issues in dietary supplements, including shelf life testing, regulatory implications, and standardizing botanical extracts. Experts address the need for critical pre-purchase research to protect consumers from potentially dangerous or ineffective products.